Noninvasive management of the diabetic foot with critical limb ischemia: Current options and future perspectives

Therapeutic Advances in Endocrinology and Metabolism

Volumn 2, Issue 6, 2011, Pages 247-255

  Weck, Mathias ^a   Slesaczeck, Torsten ^a   Münch, Dirk ^a   Nanning, Thomas ^a   Rietzsch, Hannes ^b   Weiss, Norbert ^b   Bornstein, Stefan ^b   Barthel, Andreas ^b   Paetzold, Hartmut ^a   Florek, Hans Joachim ^a  

^a Weißeritztal Kliniken GmbH Freital Dippoldiswalde   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

autologous bone marrow transplantation; critical limb ischemia; diabetic foot; prostaglandins; therapy; urokinase

Indexed keywords

FIBRINOGEN; PLACEBO; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E1; UROKINASE;

ANKLE BRACHIAL INDEX; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW DERIVED MONONUCLEAR CELL TRANSPLANTATION; CELL TRANSPLANTATION; CLAUDICATION; CRITICAL LIMB ISCHEMIA; DIABETIC FOOT; ENDOTHELIAL PROGENITOR CELL; FIBRINOGEN BLOOD LEVEL; HUMAN; LEG REVASCULARIZATION; LEG ULCER; LIMB ISCHEMIA; LIMB PERFUSION; LOW DRUG DOSE; MORTALITY; NON INVASIVE PROCEDURE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMA VISCOSITY; PRIORITY JOURNAL; ULCER HEALING;

EID: 84155192521     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018811427721     Document Type: Article

References (63)

1. Alexandrescu V. Hubermont G. Philips Y. Guillaumie B. Ngongang C. Coessens V. et al. (2009) Combined primary subintimal and endoluminal angioplasty for ischaemic inferior-limb ulcers in diabetic patients: 5-years practice in a multidisciplinary ‘diabetic foot’ service. Eur J Vas Endovasc Surg 37: 448–456.
2. Altstaedt H. Berzewski B. Breddin H. Brockhaus W. Bruhn H. Cachovan M. et al. (1993) Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukot Essent Fatty Acids 49: 573–578.
3. Amann B. Luedemann C. Ratei R. Schmidt-Lucke J. (2009) Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant 18: 371–380.
4. Amann B. Luedemann C. Rückert R. Lawall H. Liesenfeld B. Schneider M. et al. (2008) Design and rationale of a randomized, double-blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT-CLI). Vasa 37: 319–325.
5. Amendt K. (2005) PGE 1 and other prostaglandins in the treatment of intermittent claudication: a metaanalysis. Angiology 56: 409–415.
6. Asahara T. Masuda H. Takahashi T. Kalka C. Pastore C. Silver M. et al. (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circulation Res 85: 221–228.
7. Bartsch T. Brehm M. Zeus T. Högler G. Wernet P. Strauer B. (2007) Transplantation of autologous mononuclear bone marrow stem cells in patients with peripheral arterial disease (The TAM-PAD Study). Clin Res Cardiol 96: 891–899.
8. Belch J. McKay A. McArdle B. Leiberman P. Pollock J. Lowe G. et al. (1983) Epoprostenol (prostacycline) and severe arterial disease: A double-blind trial. Lancet 1: 315–317.
9. Boyum A. Brincker F. Martinsen I. Lea T. Lovhang D. (2002) Separation of human lymphocytes from citrated blood by density gradient (Nyco Prep) centrifugation: monocyte depletion depending upon activation of membrane potassium channels. Scand J Immunol 56: 76–84.
10. Creutzig A. Lehmacher W. Elze M. (2004) Meta-analysis of randomised controlled prostaglandin E 1 studies in peripheral arterial occlusive disease stages III and IV. Vasa 33: 137–144.
11. Cronenwett J. Zelenock G. Whitehous W. Lindenauer S. Graham L. Stanley J. (1986) Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease. Surgery 100: 369–375
12. Duthois S. Cailleux N. Benosman B. Levesque H. (2003) Tolerance of iloprost and results of treatment chronic severe lower limb ischaemia in diabetic patients. A retrospective study of 64 consecutive cases. Diab Metab 29: 36–43.
13. Fadini G. Agostini C. Avogaro A. (2010) Autologous stem cell therapy for peripheral arterial disease. Meta-analysis and systematic review of the literature. Atherosclerosis 209: 10–17.
14. Faglia E. Clerici G. Clerissi J. Gabrielli L. Losa S. Mantero M. et al. (2006) Early and five-year amputation and survival rate of diabetic patients with critical limb ischemia: data of a cohort study of 564 patients. Eur J Vasc Endovasc Surg 32: 484–490.
15. Faglia E. Clerici G. Clerissi J. Gabrielli L. Losa S. Mantero M. et al. (2009) Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study. Diabetes Care 32: 822–827.
16. Helisch A. Schaper W. (2003) Arteriogenesis: The development and growth of collateral arteries. Micocirculation 10: 83–97.
17. Hicken G. Lossing A. Rubin B. Aro L. Ameli F. (1995) Intra-arterial infusion of urokinase for acute, critical ischemia in the lower limb. Can J Surg 38: 486–491.
18. Hirsch A. Haskal Z. Hertzer N. Bakal C. Creager M. Halperin J. et al. (2006) ACC/AHA 2005 Practical guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines. Circulation 113: e463–e654.
19. Humpert P. Bärtsch U. Konrade I. Hammes H.-P. Morcos M. Kasper M. et al. (2005) Locally applied mononuclear bone marrow cells restore angiogenesis and promote wound healing in a type 2 diabetic patient. Exp Clin Endocrinol Diabetes 113: 538–540.
20. ICAI (Ischemia Cronica degli Arti Inferiori) Study Group (1999) Prostanoids for chronic criticial leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. Ann Intern Med 130: 412–421.
21. Iversen M. Tell G. Riise T. Hanestad B. Østbye T. Graue M. et al. (2009) History of foot ulcer increases mortality among individuals with diabetes: ten-year follow-up of the Nord-Trøndelag Health Study, Norway. Diabetes Care 32: 2193–2199.
22. Kalka C. Masuda H. Takahashi T. Kalka-Moll W. Silver M. Kearney M. et al. (2000) Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 97: 3422–3427.
23. Kamihata H. Matsubara H. Nishihue T. Fujiyama S. Tsutsumi Y. Ozono R. et al. (2001) Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 104: 1046–1052.
24. Kolvenbach R. Kreissig C. Cagiannos C. Afifi R. Schmaltz E. (2010) Intraoperative adjunctive stem cell treatment in patients with critical limb ischemia using a novel point-of-care device. Ann Vasc Surg 24: 367–372.
25. Lawall H. Bramlage P. Amann B. (2010) Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost 103: 696–709.
26. Lawall H. Diehm C. Baler K. Gail D. Heidrich H. Huppert P. (2009 a) Deutsche Gesellschaft für Angiologie/Gesellschaft für Gefäßmedizin. Leitlinien zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (PAVK). http://www.awmf.de/
27. Lawall H. Gorriahn H. Amendt K. Ranft J. Bramlage P. Diehm C. (2009 b) Long-term outcomes after medical and interventional therapy of critical limb ischemia. Eur J Intern Med 20: 616–621.
28. Leschke M. (2008) Rheology and coronary heart disease. Dtsch Med Wochenschr 133(Suppl. 8): S270–S273.
29. Leschke M. Klimek W. Jung F. (2003) Rheological determinants of end-organ damage. Internist 44: 853–863.
30. Leschke M. Motz W. Strauer B. (1986) Hemorheologic therapy applications in coronary heart disease. Wien Med Wochenschr 136: 17–24.
31. Leschke M. Schoebel F. Mecklenbeck W. Stein D. Jax T. Müller-Gärtner H. et al. (1996) Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: a randomized dose-response trial. J Am Coll Cardiol 27: 575–584.
32. Leschke M. Schoebel F. Strauer B. (1997) Low-dose intermittent urokinase therapy in chronic symptomatic end-stage arterial disease–clinical relevance for patients with coronary artery disease or peripheral arterial occlusive disease. Clin Hemorheol Microcirc 17: 59–66.
33. Loosemore T. Chalmers T. Dormandy J. (1994) A meta-analysis of randomized placebo controlled trials in Fontaine Stages III and IV peripheral occlusive arterial disease. Int Angiol 13: 133–142.
34. Matoba S. Tatsumi T. Murohara T. Imaizumi T. Katsuda Y. Ito M. et al. (2008) Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 156: 1010–1018.
35. Miyamoto M. Yasutake M. Takano H. Takagi H. Takagi G. Mizuno H. et al. (2004) Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization by 99m Tc-tetrofosmin (TF) perfusion scintigraphy. Cell Transplant 13: 429–437.
36. Norgen L. Alwmark A. Angquist K. Hedberg B. Bergqvist D. Takolander R. et al. (1990) A stable prostacyclin analogue (iloprost) in the treatment of ischaemic ulcers of the lower limb. A Scandinavian–Polish placebo controlled, randomised multicenter study. Eur J Vasc Surg 4: 463–467.
37. Norgren L. Hiatt W. Dormandy J. Nehler M. Harris K. Fowkes F. (2007) TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 33(Suppl. 1): S1–S75.
38. Partsch H. Jochmann W. (1993) [Urokinase in refractory lower leg ulcers: therapy with retrograde intravenous pressure infusion]. Wien Med Wochenschrs 143: 187–190.
39. Peters A. Schoebel F. Jax T. Neubaur T. Strauer B. Leschke M. (1999) Long-term Urokinase Therapy and Isovolemic Hemodilution: A Clinical and Hemodynamic Comparison in Patients with Refractory Angina Pectoris. Int J Angiol 8: 44–49.
40. Prochaska V. Gumulec J. Chmelova J. Klement P. Klement G. Jonsza T. et al. (2009) Autologous bone marrow stem cell transplantation in patients with end-stage chronical limb ischemia and diabetic foot. Vnitr Lek 55: 173–178.
41. Prompers L. Huijberts H. Apelqvist J. Jude E. Piaggesi A. Bakker K. et al. (2007) High prevalence of ischemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale Study. Diabetologia 50: 18–25.
42. Rietzsch H. Panzer I. Selisko T. Julius U. Jabs N. Reimann M. et al. (2008) Heparin-induced extracorporeal LDL precipitation (H.E.L.P.) in diabetic foot syndrome-preventive and regenerative potential? Horm Metab Res 40: 487–490.
43. Ryden L. Standl E. Bartnik M. van den Berghe G. Betteridge J. de Boer M. et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88–136.
44. Schuler J. Flanigan D. Holcroft J. Ursprung J. Mohrland J. Pyke J. (1984) Efficacy of prostaglandin E 1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double-blind, multicenter clinical trial. J Vasc Surg 1: 160–170.
45. Shintani S. Murohara T. Ikeda H. Ueno T. Honma T. Katoh A. et al. (2001) Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103: 2776–2779.
46. Singh N. Armstrong D. Lipsky B. (2005) Preventing foot ulcers in patients with diabetes. J Am Med Assoc 293: 217–228.
47. Stiegler H. Diehm C. Grom E. Martin M. Morl M. Rudofsky G. et al. (1992) Placebo controlled, double-blind study of the effectiveness of i.v. prostaglandin E 1 in diabetic patients with stage IV arterial occlusive disease. Vasa 35(Suppl.): 164–166.
48. Sumpio B. Armstrong D. Lavery L. Andros G., for the SVS/APMA writing group (2010) The role of interdisciplinary team approach in the management of the diabetic foot: a joint statement from the Society for Vascular Surgery and the American Podiatric Medical Association. J Vasc Surg 51: 1504–1506.
49. Takahashi T. Kalka C. Masuda H. Chen D. Silver M. Kearney M. et al. (1999) Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5: 434–438.
50. Tateishi-Yuyama E. Matsubara H. Murohara T. Ikeda U. Shintani S. Masaki H. et al. (2002) Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360: 427–435.
51. Telles G. Campbell W. Wood R. Collin J. Baird R. Morris P. (1984) Prostaglandin E 1 in severe lower limb ischaemia: a double blind controlled trial. Br J Surg 71: 506–508.
52. Trübestein G. Diehm C. Gruss J. Horsch S. (1987) Prostaglandin E 1 in chronic arterial disease: a multicenter study. Vasa 17(Suppl.): 39–43.
53. Turan R. Ortakm J. Akin I. Kische S. Schneider H. Turan C. et al. (2011) Improved mobilization of the CD 34+ and CD 133+ bone marrow-derived circulation progenitor cells by freshly isolated intracoronary bone marrow cell transplantation in patients with ischemic heart disease. Stem cells Dev 20: 1491–1501.
54. UK Severe Limb Ischaemia Study Group (1991) Treatment of limb threating ischaemia with intravenous iloprost: a randomised double-blind placebo controlled study. Eur J Vasc Surg 5: 511–516.
55. Unthank J. Sheridan K. Dalsing M. (2004) Collateral growth in the peripheral circulation: a review. Vasc Endovascular Surg 38: 291–313.
56. van Tongeren R. Hamming J. Fibbe W. van Weel V. Frerichs S. Stiggelbout A. et al. (2008) Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: a clinical trial in patients with advanced limb ischemia. J Cardiovasc Surg (Torino) 49: 51–58.
57. Weck M. Laage C. Schab T. Mölle A. (2001) Low-dose urokinase therapy in acute angioneuropathic diabetic foot syndrome (DFS). Diab Stoffw 10: 13–21.
58. Weck M. Panzner I. Schellong S.M. (2006) Diagnostik und Therapie des diabetischen Fußes. UNI MED: Bremen, Germany.
59. Weck M. Rietzsch H. Lawall H. Pichlmeier U. Bramlage P. Schellong S. (2008) Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration. Thromb Haemost 100: 475–482.
60. Weck M. Slesaczeck T. Paetzold H. Münch D. Nanning T. von Gagern G. et al. (2010) Limb salvage experience in a Disease Management Program for the diabetic foot. Diabetes 59(Suppl. 1): A324–A325.
61. Yoshida M. Horimoto H. Mieno S. Nomura Y. Okawa H. Nakahara R. et al. (2003) Intra-arterial bone marrow cell transplantation induces angiogenesis in rat hindlimb ischemia. Eur Surg Res 35: 86–91.
62. Zeller T. (2007) Current state of endovascular treatment of femoro-popliteal artery disease. Vasc Med 3: 223–234.
63. Zeller T. Sixt S. Rastan A. (2009) New techniques for endovascular treatment of peripheral artery disease with focus on chronic critical limb ischemia. Vasa 38: 3–12.